TrialLancet (London, England)2021

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Xinxue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.